Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

Authors

S. M. O'Brien
J. C. Byrd
P. Hillmen
S. Coutre
J. R. Brown
P. M. Barr
J. C. Barrientos, Zucker School of Medicine at Hofstra/Northwell
S. Devereux
T. Robak
J. A. Burger
+8 additional authors

Publication Date

2019

Journal Title

Am J Hematol

Volume Number

94

Issue Number

5

Pages

554 - 562

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

General Internal Medicine

PMID

30767298

DOI

10.1002/ajh.25436